Printer Friendly

Company completes development of stem cell liquid suspension.

SALT LAKE CITY, Utah, May 16, 2016 -- Predictive Technology Group, Inc. (OTC PINK:PRED) said its subsidiary, Predictive Biotech, Inc. has finished developing a new allograft stem cell product derived from umbilical cord blood (UCB).

The use of UCB stem cells have gained popularity in medical science owing to their ability to transform into any type of human cells.

UCB refers to the blood and tissue that remains in the attached umbilical cord and placenta after childbirth.

UCB derived stem cells might be used in wound healing, pain management, and genetic and hematopoietic disorders.

The CoreCell liquid suspension product is rich in proteins and cells.

Predictive Biotech is negotiating with several orthobiologic distributors to launch the product here and abroad.

The company is also considering private label opportunities and plans to eventually distribute the product through its own direct sales organization.



COPYRIGHT 2016 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Advanced Stem Cell Technology
Publication:Stem Cell Business News
Date:May 16, 2016
Previous Article:Company regenerates esophagus in preclinical work with Mayo Clinic.
Next Article:European researchers to use Wafergen Single-Cell Systems.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters